2021
Evaluation of disparities in impact of mental health intensive case management on 6-month symptoms, functioning, and quality of life between black and white veterans diagnosed with schizophrenia
Browne J, Mohamed S. Evaluation of disparities in impact of mental health intensive case management on 6-month symptoms, functioning, and quality of life between black and white veterans diagnosed with schizophrenia. Schizophrenia Research 2021, 253: 68-74. PMID: 34247886, DOI: 10.1016/j.schres.2021.07.002.Peer-Reviewed Original ResearchConceptsEqual-access health care systemVeterans Health AdministrationWhite veteransHealth care systemClinical characteristicsClinical historySystem involvementMental health recovery programsCare systemService delivery differencesNational program evaluation dataSix-month changesEvaluation of disparitiesIntensive case managementQuality of lifeSubstantial health disparitiesMajority of outcomesJustice system involvementBaseline characteristicsClinical outcomesClinic settingService useSociodemographic factorsHealth AdministrationHealth disparities
2016
Comparison of burden among family members of patients diagnosed with schizophrenia and bipolar disorder in a large acute psychiatric hospital in China
Zhou Y, Rosenheck R, Mohamed S, Ou Y, Ning Y, He H. Comparison of burden among family members of patients diagnosed with schizophrenia and bipolar disorder in a large acute psychiatric hospital in China. BMC Psychiatry 2016, 16: 283. PMID: 27515535, PMCID: PMC4980784, DOI: 10.1186/s12888-016-0962-y.Peer-Reviewed Original ResearchConceptsFamily burdenBipolar disorderPsychiatric hospitalDifference of burdenWeeks of patientsMethodsTwo hundred fortyCross-sectional studyFamilies of patientsAcute psychiatric hospitalLarge psychiatric hospitalBipolar disorder patientsQuality of lifeComparison of burdenClinical featuresAcute patientsPredictive factorsCaregiver burdenHundred fortyDisorder patientsSchizophrenic patientsBipolar patientsPatientsSchizophrenia patientsSuicidal riskCaregivers' perceptions
2015
Randomized Trial of the Effect of Four Second-Generation Antipsychotics and One First-Generation Antipsychotic on Cigarette Smoking, Alcohol, and Drug Use in Chronic Schizophrenia
Mohamed S, Rosenheck RA, Lin H, Swartz M, McEvoy J, Stroup S. Randomized Trial of the Effect of Four Second-Generation Antipsychotics and One First-Generation Antipsychotic on Cigarette Smoking, Alcohol, and Drug Use in Chronic Schizophrenia. The Journal Of Nervous And Mental Disease 2015, 203: 486-492. PMID: 26075840, DOI: 10.1097/nmd.0000000000000317.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAlcoholismAntipsychotic AgentsBenzodiazepinesChronic DiseaseComorbidityCross-Sectional StudiesDibenzothiazepinesDouble-Blind MethodFemaleHumansIllicit DrugsMaleMiddle AgedOlanzapinePerphenazinePiperazinesPsychiatric Status Rating ScalesQuetiapine FumarateRisperidoneSchizophreniaSchizophrenic PsychologySmokingSmoking PreventionSubstance-Related DisordersThiazolesYoung AdultConceptsSecond-generation antipsychotic drugsAntipsychotic drugsFirst-generation antipsychoticsSecond-generation antipsychoticsIntervention Effectiveness (CATIE) studySecondary outcome dataClinical Antipsychotic TrialsFirst-generation drugsSubstance use outcomesCigarette smokingSchizophrenia trialsChronic schizophreniaAntipsychotic TrialsOutcome dataNicotine useDrug useSecondary analysisPast weekAntipsychoticsEffectiveness studiesPatientsSubstance useUse outcomesTrialsDrugs
2014
Insight in inpatients with schizophrenia: Relationship to symptoms and neuropsychological functioning
Zhou Y, Rosenheck R, Mohamed S, Zhang J, Chang Q, Ou Y, Sun B, Ning Y, He H. Insight in inpatients with schizophrenia: Relationship to symptoms and neuropsychological functioning. Schizophrenia Research 2014, 161: 376-381. PMID: 25533592, DOI: 10.1016/j.schres.2014.12.009.Peer-Reviewed Original ResearchAssociation of symptom severity, insight and increased pharmacologic side effects in acutely hospitalized patients with schizophrenia
Zhang J, Rosenheck R, Mohamed S, Zhou Y, Chang Q, Ning Y, He H. Association of symptom severity, insight and increased pharmacologic side effects in acutely hospitalized patients with schizophrenia. Comprehensive Psychiatry 2014, 55: 1914-1919. PMID: 25217308, DOI: 10.1016/j.comppsych.2014.07.018.Peer-Reviewed Original ResearchConceptsPharmacologic side effectsSevere side effectsGreater medication complianceHigher medication dosagesPANSS total scoreSevere symptomsSide effectsMedication complianceMedication dosageITAQ scoresHigh dosesTotal scorePoor treatment complianceSide effect scoresLarge psychiatric hospitalRelationship of symptomsNegative Syndrome ScaleTreatment Attitudes QuestionnaireStepwise multiple linear regression analysisInteraction of symptomsInsightful patientsTreatment emergentHospital dischargePrescribed medicationsTreatment complianceInsight and attitudes towards medication among inpatients with chronic schizophrenia in the US and China
Mohamed S, Rosenheck R, He H, Yuping N. Insight and attitudes towards medication among inpatients with chronic schizophrenia in the US and China. Social Psychiatry And Psychiatric Epidemiology 2014, 49: 1063-1070. PMID: 24549835, DOI: 10.1007/s00127-014-0824-1.Peer-Reviewed Original ResearchConceptsDrug Attitude InventorySchizophrenia symptomsPsychiatric hospitalOverall severityMeasures of insightGuangzhou Psychiatric HospitalTime of admissionBenefits of medicationsLarge psychiatric hospitalNegative Syndrome ScaleTreatment Attitudes QuestionnaireSymptoms of schizophreniaAcceptance of medicationHospitalized patientsAntipsychotic treatmentDAI scoresChronic schizophreniaMedicationsAnalysis of covarianceSyndrome ScaleMental illnessBivariate analysisSymptomsLarger studySchizophrenia
2012
Does Antidepressant Treatment Improve Cognition in Older People with Schizophrenia or Schizoaffective Disorder and Comorbid Subsyndromal Depression?
Dawes SE, Palmer BW, Meeks T, Golshan S, Kasckow J, Mohamed S, Zisook S. Does Antidepressant Treatment Improve Cognition in Older People with Schizophrenia or Schizoaffective Disorder and Comorbid Subsyndromal Depression? Neuropsychobiology 2012, 65: 168-172. PMID: 22456094, PMCID: PMC3701889, DOI: 10.1159/000331141.Peer-Reviewed Original ResearchConceptsSchizoaffective disorderCognitive deficitsDepression Rating Scale scoresHamilton Depression Rating ScaleFlexible-dose treatmentAntidepressant treatment responseDepression Rating ScaleTreatment of depressionMajor depressive disorderRating Scale scoresBaseline cognitive statusPlacebo groupAntidepressant medicationCurrent medicationsPlacebo augmentationFunctional disabilityCognitive composite scoreSubsyndromal depressionDepressive disorderSubsyndromal symptomsTreatment responseTreatment groupsDose treatmentScale scoreCognitive status
2011
Narrative evolution and assimilation of problematic experiences in a case of pharmacotherapy for schizophrenia
Osatuke K, Reid M, Stiles WB, Kasckow JW, Zisook S, Mohamed S. Narrative evolution and assimilation of problematic experiences in a case of pharmacotherapy for schizophrenia. Psychotherapy Research 2011, 21: 41-53. PMID: 20845225, DOI: 10.1080/10503307.2010.508760.Peer-Reviewed Original ResearchAdaptation, PsychologicalAntidepressive Agents, Second-GenerationAntipsychotic AgentsAwarenessCitalopramDefense MechanismsDepressive DisorderDrug Therapy, CombinationHumansInternal-External ControlInterview, PsychologicalLongitudinal StudiesMaleMiddle AgedNarrationProblem SolvingPsychotherapySchizophreniaSchizophrenic Psychology
2010
Impact of second-generation antipsychotics and perphenazine on depressive symptoms in a randomized trial of treatment for chronic schizophrenia.
Addington DE, Mohamed S, Rosenheck RA, Davis SM, Stroup TS, McEvoy JP, Swartz MS, Lieberman JA. Impact of second-generation antipsychotics and perphenazine on depressive symptoms in a randomized trial of treatment for chronic schizophrenia. The Journal Of Clinical Psychiatry 2010, 72: 75-80. PMID: 20868641, PMCID: PMC5052810, DOI: 10.4088/jcp.09m05258gre.Peer-Reviewed Original ResearchConceptsMajor depressive episodeSecond-generation antipsychoticsDSM-IV-defined schizophreniaCurrent major depressive episodeClinical practice recommendationsTrial of treatmentClinical practice guidelinesTreatment of depressionCalgary Depression ScaleClinical Antipsychotic TrialsSecond-generation drugsSymptoms of depressionPhase 1 analysisTardive dyskinesiaDepressive episodeChronic schizophreniaAntipsychotic TrialsPractice guidelinesDepression ScaleDepressive symptomsTreatment groupsBaseline scoresPatientsAntipsychoticsPractice recommendationsAugmentation with citalopram for suicidal ideation in middle-aged and older outpatients with schizophrenia and schizoaffective disorder who have subthreshold depressive symptoms: a randomized controlled trial.
Zisook S, Kasckow JW, Lanouette NM, Golshan S, Fellows I, Vahia I, Mohamed S, Rao S. Augmentation with citalopram for suicidal ideation in middle-aged and older outpatients with schizophrenia and schizoaffective disorder who have subthreshold depressive symptoms: a randomized controlled trial. The Journal Of Clinical Psychiatry 2010, 71: 915-22. PMID: 20361918, DOI: 10.4088/jcp.09m05699gre.Peer-Reviewed Original ResearchConceptsBaseline suicidal ideationHamilton Depression Rating ScaleDepression Rating ScaleSubthreshold depressive symptomsCalgary Depression Rating ScaleDepressive symptomsSuicidal ideationSchizoaffective disorderClinical Global Impressions-SeverityBeck Hopelessness ScaleDSM-IV-diagnosed schizophreniaRating ScaleTreatment-emergent suicidal ideationPlacebo-controlled trialSuicidal ideation measuresItem 3Citalopram augmentationFinal visitPlacebo augmentationSecondary outcomesPrimary outcomeOlder outpatientsInterSePT ScaleCitalopramPlacebo
2008
Citalopram augmentation for subsyndromal symptoms of depression in middle-aged and older outpatients with schizophrenia and schizoaffective disorder: a randomized controlled trial.
Zisook S, Kasckow JW, Golshan S, Fellows I, Solorzano E, Lehman D, Mohamed S, Jeste DV. Citalopram augmentation for subsyndromal symptoms of depression in middle-aged and older outpatients with schizophrenia and schizoaffective disorder: a randomized controlled trial. The Journal Of Clinical Psychiatry 2008, 70: 562-71. PMID: 19192468, DOI: 10.4088/jcp.08m04261.Peer-Reviewed Original ResearchConceptsQuality of lifeSubsyndromal symptomsSchizoaffective disorderOlder patientsOlder outpatientsTreatment groupsRandomized placebo-controlled trialRating ScaleFlexible-dose treatmentSecondary efficacy analysesPlacebo-controlled trialCurrent antipsychotic medicationsDepression Rating ScaleGeneral medical healthHamilton Rating ScaleCalgary Depression Rating ScaleYears of ageDSM-IV schizophreniaCitalopram augmentationAdverse eventsPlacebo augmentationEfficacy analysisAntipsychotic medicationStudy criteriaDimensions of schizophreniaCross-sectional and Longitudinal Relationships Between Insight and Attitudes Toward Medication and Clinical Outcomes in Chronic Schizophrenia
Mohamed S, Rosenheck R, McEvoy J, Swartz M, Stroup S, Lieberman JA. Cross-sectional and Longitudinal Relationships Between Insight and Attitudes Toward Medication and Clinical Outcomes in Chronic Schizophrenia. Schizophrenia Bulletin 2008, 35: 336-346. PMID: 18586692, PMCID: PMC2659303, DOI: 10.1093/schbul/sbn067.Peer-Reviewed Original ResearchConceptsPositive medication attitudesMedication attitudesSymptoms of schizophreniaSchizophrenia symptomsGreater medication complianceDrug Attitude InventoryRelationship of insightClinical Antipsychotic TrialsTreatment Attitudes QuestionnaireGreater patient understandingLevel of depressionMixed model regression analysisLower symptom levelsRecovery-oriented servicesClinical outcomesMedication adherenceMedication complianceChronic schizophreniaAntipsychotic TrialsPatient understandingModel regression analysisMedicationsCommunity functioningPsychosocial rehabilitationSymptomsRelationship of Cognition and Psychopathology to Functional Impairment in Schizophrenia
Mohamed S, Rosenheck R, Swartz M, Stroup S, Lieberman JA, Keefe RS. Relationship of Cognition and Psychopathology to Functional Impairment in Schizophrenia. American Journal Of Psychiatry 2008, 165: 978-987. PMID: 18450928, DOI: 10.1176/appi.ajp.2008.07111713.Peer-Reviewed Original ResearchInsight, quality of life, and functional capacity in middle‐aged and older adults with schizophrenia
Roseman AS, Kasckow J, Fellows I, Osatuke K, Patterson TL, Mohamed S, Zisook S. Insight, quality of life, and functional capacity in middle‐aged and older adults with schizophrenia. International Journal Of Geriatric Psychiatry 2008, 23: 760-765. PMID: 18205246, PMCID: PMC3428424, DOI: 10.1002/gps.1978.Peer-Reviewed Original Research
2007
Subsyndromal Depressive Symptoms in Middle-Aged and Older Persons with Schizophrenia
Zisook S, Montross L, Kasckow J, Mohamed S, Palmer BW, Patterson TL, Golshan S, Fellows I, Lehman D, Solorzano E. Subsyndromal Depressive Symptoms in Middle-Aged and Older Persons with Schizophrenia. American Journal Of Geriatric Psychiatry 2007, 15: 1005-1014. PMID: 18056819, DOI: 10.1097/jgp.0b013e3180a725ec.Peer-Reviewed Original ResearchMeSH KeywordsAge FactorsChronic DiseaseCitalopramComorbidityDepressionDepressive Disorder, MajorDouble-Blind MethodFemaleFollow-Up StudiesHealth StatusHumansMaleMiddle AgedPlacebosPsychiatric Status Rating ScalesPsychotic DisordersSchizophreniaSchizophrenic PsychologySelective Serotonin Reuptake InhibitorsSuicideTreatment OutcomeConceptsSubsyndromal depressive symptomsDepressive symptomsOlder patientsClinical featuresSchizoaffective disorderNegative symptomsHamilton Depression Rating ScaleImportant clinical dimensionGeneral medical conditionsDepression Rating ScaleSpecific depressive symptomsMental functioningSubstantial morbiditySevere akathisiaMovement abnormalitiesChronic schizophreniaMedical conditionsDepression groupOverall psychopathologyIntervention studiesDepressive symptomatologyPatientsSymptomsOlder personsGeneral psychopathologyInsight in schizophrenia: a review of etiological models and supporting research
Osatuke K, Ciesla J, Kasckow JW, Zisook S, Mohamed S. Insight in schizophrenia: a review of etiological models and supporting research. Comprehensive Psychiatry 2007, 49: 70-77. PMID: 18063044, DOI: 10.1016/j.comppsych.2007.08.001.Peer-Reviewed Original ResearchSuicidality in middle aged and older patients with schizophrenia and depressive symptoms: relationship to functioning and Quality of Life
Kasckow J, Montross L, Golshan S, Mohamed S, Patterson T, Sollanzano E, Zisook S. Suicidality in middle aged and older patients with schizophrenia and depressive symptoms: relationship to functioning and Quality of Life. International Journal Of Geriatric Psychiatry 2007, 22: 1223-1228. PMID: 17506025, PMCID: PMC3118557, DOI: 10.1002/gps.1817.Peer-Reviewed Original ResearchConceptsQuality of lifeMedication Management Ability AssessmentDepressive symptomsQLS scoresUCSD Performance-based Skills AssessmentOlder patientsSocial Skills Performance AssessmentLeast mild degreeDSM-IV criteriaMore depressive symptomsWorse qualityMean ageISS scoreMedication managementMajor depressionMild degreeHeinrichs QualitySchizoaffective disorderPatientsPerformance-Based Skills AssessmentSignificant associationSpearman's rho correlational analysisWorse functioning
2006
Neurocognitive functioning in dually diagnosed middle aged and elderly patients with alcoholism and schizophrenia
Mohamed S, Bondi MW, Kasckow JW, Golshan S, Jeste DV. Neurocognitive functioning in dually diagnosed middle aged and elderly patients with alcoholism and schizophrenia. International Journal Of Geriatric Psychiatry 2006, 21: 711-718. PMID: 16862606, DOI: 10.1002/gps.1528.Peer-Reviewed Original ResearchConceptsAlcohol abuse/dependenceAbuse/dependenceSchizophrenia patientsCognitive statusAlcohol useHigher cognitive functionsWorse cognitive scoresQuality of lifeYounger schizophrenia patientsOlder groupNeuropsychological functioningNeurocognitive functioningCognitive functionCognitive scoresWorse cognitionIntervention researchCognitionDiagnosis of schizophreniaSame-aged groupPsychopathologic assessmentSchizoaffective disorderSymptom profilesLater lifeAge groupsSchizophrenia
2005
Stability of Cognitive Performance in Older Patients With Schizophrenia: An 8-Week Test-Retest Study
Harvey PD, Palmer BW, Heaton RK, Mohamed S, Kennedy J, Brickman A. Stability of Cognitive Performance in Older Patients With Schizophrenia: An 8-Week Test-Retest Study. American Journal Of Psychiatry 2005, 162: 110-117. PMID: 15625208, DOI: 10.1176/appi.ajp.162.1.110.Peer-Reviewed Original ResearchMeSH KeywordsAge FactorsAgedAlgorithmsAmbulatory CareAntipsychotic AgentsCognition DisordersFemaleFollow-Up StudiesHumansMaleMiddle AgedNeuropsychological TestsPsychiatric Status Rating ScalesPsychometricsPsychomotor PerformanceReproducibility of ResultsSchizophreniaSchizophrenic PsychologySeverity of Illness IndexConceptsCognitive measuresCognitive performancePractice effectsComprehensive neuropsychological test batteryTest scoresReliable change index methodCognitive-enhancing medicationsNeuropsychological test batteryCognitive test scoresSignificant test-retest correlationsModest cognitive improvementTest-retest correlationsTest-retest performanceCognitive improvementTest batterySecond-generation antipsychotic medicationsTest-retest errorSchizophrenia patientsRetest studyAntipsychotic medicationAlternate formsConventional antipsychotic medicationsSchizophreniaSpurious improvementPrior studies
2001
Citalopram augmentation of antipsychotic treatment in older schizophrenia patients
Kasckow J, Mohamed S, Thallasinos A, Carroll B, Zisook S, Jeste D. Citalopram augmentation of antipsychotic treatment in older schizophrenia patients. International Journal Of Geriatric Psychiatry 2001, 16: 1163-1167. PMID: 11748776, DOI: 10.1002/gps.508.Peer-Reviewed Original ResearchConceptsCitalopram augmentationScale scoreClinical Global Impression Scale scoresHamilton Depression Rating Scale scoresLarge double-blind studyDepression Rating Scale scoresAugmentation of antipsychoticsUsefulness of antidepressantsDouble-blind studySingle-blind trialMajor side effectsOlder schizophrenia patientsRating Scale scoresStable dosesElderly patientsOlder patientsAntipsychotic treatmentCitalopram groupDepressive symptomsSide effectsPatientsSchizophrenia patientsControl groupNegative symptomsAntipsychotics